
Formulation Recommendation



80/160 mg APAP Orally Disintegrating Tablet (ODT)

| Composition | % (By Weight) | mg / Tablet |
|----------------------|---------------|-------------|
| 1 Actimask® APAP 92M | 21.74 | 86.96 |
| 2 Pharmaburst® 500 | 72.91 | 291.64 |
| 3 Lubripharm® SSF | 2.50 | 10.00 |
| 4 Bubblegum Flavor | 2.00 | 8.00 |
| 5 Sucralose | 0.75 | 3.00 |
| ● 6 FD&C Red #27 | 0.10 | 0.40 |
| F | 400.00 | |



General Tablet Characteristics

| 80 mg APAP ODT | Tablet Thickness (mm) | Tablet Hardness (kP) | Tablet Disintegration (s) | Friability (%) |
|-------------------|-----------------------------|----------------------------|---------------------------|-------------------|
| Average | 5.87 | 3.30 | 12.60 | 0.25 |
| St. Dev. | 0.02 | 0.19 | 1.67 | 0.25 |

| 160 mg APAP ODT | Tablet Thickness (mm) | Tablet Hardness (kP) | Tablet Disintegration (s) | Friability (%) |
|--------------------|-----------------------------|----------------------------|---------------------------|-------------------|
| Average | 6.36 | 5.16 | 27.00 | 0.6 |
| St. Dev. | 0.03 | 0.30 | 4.00 | 0.6 |

Method

- Weigh the components individually and screen all non-lubricant and non-colorants using a #20-mesh sieve. Seperately, take the Lubripharm and FD&C Red and co-screen using a #20-mesh sieve.
- Mix all ingredients, with the exception of Lubripharm and FD&C Red in an 8-qt V-blender at 25rpm for 15 minutes.
- 3. Add the Lubripharm and FD&C Red to the first mixture and blend for an additional 5 minutes at 25rpm.
- 4. Compress the formulation to 400mg tablets on a rotary tablet press outfitted with 0.4930" Arc Square type "D" punches, operated at 25rpm to a tablet hardness of 3kP. Alternatively, the 160mg APAP ODT can be manufactured by compressing 800mg tablets at 25rpm with 0.5" Arc Square type "D" punches to a tablet hardness of 5kP.

Your Partner for Formulating Success

Americas SPI Pharma, Inc. Rockwood Office Park 503 Carr Rd., Suite 210 Wilmington, DE 19809

T 302 576 8600 800 789 9755 Ext. 8600 F 302 576 8567 Europe/Middle East/ Africa SPI Pharma SAS Chemin du Vallon du Maire 13240 Septemes-Les Vallons France

T 33 4 9196 3600 F 33 4 9196 3633 Asia/Pacific SPI Pharma, Inc – India Branch 21 B, Veerasandra Industrial Area Hosur Road, Bangalore – 560100 Karnataka, India

T 91 80 3027 0005 T 61 2 9475 2200 F 91 80 3027 0050 F 61 2 9475 2211

Australia Distribution Company

Anzchem 1 Braidwood Street Enfield NSW 2136

Australia

www.spipharma.com



All trademarks are the property of SPI Pharma. Copyright SPI Pharma 2013. The information contained in this document is proprietary to SPI Pharma and may not be used or disseminated inappropriately. The information and recommendations contained herein are to the best of SPI Pharma, Inc.'s knowledge reliable and accurate. Any recommendations are made without warranty, either implied or expressed, due to the variations in equipment, conditions, and methods which may be used in commercially processing the products. No warranties of any kind are made, express or implied, including those of merchantability and fitness for particular purpose, other than the products conform to current standard specifications. SPI Pharma, Inc. makes no warranty that the use of the products or formulations provided by SPI Pharma, Inc. will not infringe any trademark, trade name, copyright, patent or other rights held by any third party when used in customer's application. SPI Pharma, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damage.